Novavax (NVAX) Change in Accured Expenses (2010 - 2026)

Novavax's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$60.1 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 71.64% year-over-year to -$60.1 million in Q1 2026; TTM through Mar 2026 was -$170.8 million, a 47.45% increase from a year earlier, with the FY2025 full-year figure at -$322.6 million, up 16.35% from the prior year.
• Change in Accured Expenses retreated to -$60.1 million in Q1 2026 per NVAX's latest filing, from -$21.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $823.0 million in Q4 2022 and bottomed at -$272.5 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is -$60.1 million (2026), against an average of -$13.7 million.
• Biggest YoY gain for Change in Accured Expenses was 376.12% in 2022; the steepest drop was 316.6% in 2022.
• Year by year, Change in Accured Expenses stood at $823.0 million in 2022, then sank by 103.59% to -$29.5 million in 2023, then slumped by 43.74% to -$42.5 million in 2024, then surged by 49.27% to -$21.5 million in 2025, then slumped by 178.87% to -$60.1 million in 2026.
• Per Business Quant, the three latest NVAX Change in Accured Expenses figures stand at -$60.1 million (Q1 2026), -$21.5 million (Q4 2025), and -$26.5 million (Q3 2025).